EFSA Establishes 500mg Daily Limit for Berberine and Mandates Pregnancy Warning Labels

The European Food Safety Authority has finalized its safety assessment on berberine hydrochloride following rising reports of adverse liver interactions. Effective immediately for all new product notifications, brands must cap daily servings at 500mg and include specific mandatory warnings regarding glucose metabolism and pregnancy.

Impact on High Potency Formulations

Most premium brands currently market 1000mg to 1500mg daily doses to compete with pharmaceutical metformin alternatives. This ruling renders those formulations non-compliant for sale in the EU market. If you are holding stock of 500mg capsules with a two-capsule serving size, you must overlabel to a one-capsule serving or face market withdrawal orders.

New Mandatory Labeling Requirements

• Warning stating the product is not suitable for pregnant or lactating women
• Advice to consult a physician if taking blood glucose lowering medication
• Maximum daily dose not to exceed 500mg of berberine salts
• Restriction against use by individuals under 18 years of age

Supply Chain and Sourcing Shift

Expect a sudden surplus of 97 percent purity berberine HCl as brands cancel orders for high-dose production runs. Spot prices for berberine HCl have already dipped to 72 EUR per kg. Procurement managers should look to negotiate long-term contracts now while volumes are being redistributed, but avoid overstocking until the final transition deadline in mid-2027 is confirmed by the Commission.

For brands looking to maintain efficacy within the 500mg limit, the move is to shift toward phytosomal or liposomal delivery systems. These formats allow for lower raw material weight while maintaining plasma concentration levels that customers expect from higher doses. Expect liposomal berberine raw material costs to stabilize around 145 EUR per kg as demand scales.